A Study of the Safety and Effectiveness of a R256918 in Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the effectiveness and safety of 12 weeks of
treatment with R256918 in patients with Type 2 Diabetes Mellitus who are taking metformin.
The primary measure of effectiveness is the change in concentration of glycated hemoglobin
(HbA1c) during treatment. Glycated hemoglobin is a substance in red blood cells that is
formed when blood sugar (glucose) attaches to hemoglobin and is a measure of diabetic status.
Additional measures include fasting glucose, and lipid levels, and body weight. Safety
assessments performed during the trial include laboratory tests, vital sign measurements, and
adverse event reporting.
Phase:
Phase 2
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.